ELI LILLY AND COMPANY Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax
ELI LILLY AND COMPANY (LLY) reported Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax of $5.60 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-19.
Discontinued › Notes
us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax · last filed 2016-02-19
- ELI LILLY AND COMPANY translation adjustment functional to reporting currency, increase (decrease), gross of tax for the quarter ending 2015-12-31 was -$45.00M.
- ELI LILLY AND COMPANY translation adjustment functional to reporting currency, increase (decrease), gross of tax for the quarter ending 2015-09-30 was -$16.80M.
- ELI LILLY AND COMPANY translation adjustment functional to reporting currency, increase (decrease), gross of tax for the quarter ending 2015-06-30 was -$33.80M.
- ELI LILLY AND COMPANY translation adjustment functional to reporting currency, increase (decrease), gross of tax for the quarter ending 2015-03-31 was $101.20M.
- ELI LILLY AND COMPANY translation adjustment functional to reporting currency, increase (decrease), gross of tax for fiscal 2015 was $5.60M.
| Period end | Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax 3 month | Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax 6 month | Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax 9 month | Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax 12 month |
|---|---|---|---|---|
| 2015-12-31 | -$45.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$61.80M derived: sum of 2 quarters · filed 2016-02-19 | -$95.60M derived: sum of 3 quarters · filed 2016-02-19 | $5.60M 10-K · filed 2016-02-19 |
| 2015-09-30 | -$16.80M 10-Q · filed 2015-10-30 | -$50.60M derived: sum of 2 quarters · filed 2015-10-30 | $50.60M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | -$33.80M 10-Q · filed 2015-07-30 | $33.80M 10-Q · filed 2015-07-30 | ||
| 2015-03-31 | $101.20M derived: 10-K 12 month − 3 quarters · filed 2016-02-19 | |||
| 2014-09-30 | $0.00 10-Q · filed 2015-10-30 | $0.00 derived: sum of 2 quarters · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | |
| 2014-06-30 | $0.00 10-Q · filed 2015-07-30 | $0.00 10-Q · filed 2015-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |